Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?

Patient demand for compounded versions of FDA approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high profile concern for the brand industry.